Kenvue (NYSE:KVUE) Price Target Raised to $19.00 at Barclays

Kenvue (NYSE:KVUE) had its price target upped by investment analysts at Barclays from $18.00 to $19.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s target price would indicate a potential upside of 5.44% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research report on Wednesday, November 26th. UBS Group raised their price objective on shares of Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 18th. Canaccord Genuity Group lifted their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $23.00 to $18.00 in a research note on Friday, January 30th. Finally, Citigroup raised their price target on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, February 18th. Three investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $19.58.

Kenvue Price Performance

Kenvue stock traded down $0.23 during midday trading on Friday, reaching $18.02. The company had a trading volume of 1,120,162 shares, compared to its average volume of 48,890,094. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. Kenvue has a 12-month low of $14.02 and a 12-month high of $25.17. The company has a market capitalization of $34.54 billion, a P/E ratio of 23.40, a P/E/G ratio of 4.17 and a beta of 0.51. The firm’s fifty day simple moving average is $17.82 and its 200-day simple moving average is $17.47.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The company had revenue of $3.78 billion during the quarter, compared to analyst estimates of $3.68 billion. During the same period in the previous year, the business earned $0.26 EPS. Kenvue’s quarterly revenue was up 3.2% on a year-over-year basis. As a group, equities analysts anticipate that Kenvue will post 1.14 EPS for the current year.

Insider Activity

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of the firm’s stock in a transaction dated Friday, December 12th. The shares were purchased at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the acquisition, the director owned 27,307,632 shares in the company, valued at $474,333,567.84. The trade was a 13.27% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.68% of the company’s stock.

Institutional Trading of Kenvue

Several institutional investors have recently added to or reduced their stakes in the stock. Salomon & Ludwin LLC purchased a new position in shares of Kenvue during the third quarter worth $25,000. NBT Bank N A NY raised its holdings in shares of Kenvue by 180.3% in the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock valued at $25,000 after buying an additional 1,006 shares during the period. Cornerstone Planning Group LLC lifted its stake in Kenvue by 705.2% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares in the last quarter. Physician Wealth Advisors Inc. lifted its stake in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares in the last quarter. Finally, Elyxium Wealth LLC purchased a new position in Kenvue during the 4th quarter valued at about $26,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.